Chang-Yu Chen

Chang-Yu Chen

Auto-generated profile, based on publicly available information

Chang-Yu Chen

Krantz Family Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
ACAlex C. Y. Chen
Alex C. Y. Chen
SJSneha Jaiswal
Sneha Jaiswal
DMDaniela Martinez
Daniela Martinez
CYCansu Yerinde
Cansu Yerinde
KJKeely Ji
Keely Ji
DSDebattama R. Sen
Debattama R. Sen

17 September 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
SWSarah A. Weiss
Sarah A. Weiss
AHAmy Y. Huang
Amy Y. Huang
MFMegan E. Fung
Megan E. Fung
DMDaniela Martinez
Daniela Martinez
ACAlex C. Y. Chen
Alex C. Y. Chen
DSDebattama R. Sen
Debattama R. Sen

29 March 2018 in Journal of Biomedical Science
Verified
Journal Article
Open access
PDF file
CCChang-Yu Chen
Chang-Yu Chen
YLYung-Song Lin
Yung-Song Lin
CCChen Chien-Ho
Chen Chien-Ho
Yin-Ju ChenYin-Ju Chen
Yin-Ju Chen
Nasopharyngeal carcinoma (NPC) is a head and neck cancer with poor clinical outcomes and insufficient treatments in Southeast Asian populations. Although concurrent chemoradiotherapy has improved recovery rates of patients, poor overall survival and low efficacy are still critical problems. To improve the therapeutic efficacy, we focused on a tumor-associated protein called Annexin A2 (ANXA2). This review summarizes the mechanisms by which ANXA2 promotes cancer progression (e.g., proliferation, migration, the epithelial-mesenchymal transition, invasion, and cancer stem cell formation) and therapeutic resistance (e.g., radiotherapy, chemotherapy, and immunotherapy). These mechanisms gave us a deeper understanding of the molecular aspects of cancer progression, and further provided us with a great opportunity to overcome therapeutic resistance of NPC and other cancers with high ANXA2 expression by developing this prospective ANXA2-targeted therapy.

9 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
CCChang-Yu Chen
Chang-Yu Chen
CCChi-Long Chen
Chi-Long Chen
PCPin-Zhir Chao
Pin-Zhir Chao
JCJeng-Fong Chiou
Jeng-Fong Chiou
CKChia-Chun Kuo
Chia-Chun Kuo
CCChen Chien-Ho
Chen Chien-Ho
// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Chang-Yu Chen1, *, Yung-Song Lin2, 3, *, Chi-Long Chen4, *, Pin-Zhir Chao5, Jeng-Fong Chiou6, 7, 8, Chia-Chun Kuo6, Fei-Peng Lee9, Yung-Feng Lin1, Yu-Hsuan Sung1, Yun-Tien Lin1, Chang-Fan Li1, Yin-Ju Chen6, 10, *, Chien-Ho Chen1, * 1School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan 2Department of Otolaryngology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 3Department of Otolaryngology, Chi Mei Medical Center, Tainan, Taiwan 4Department of Pathology, Taipei Medical University Hospital; Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 5Department of Otolaryngology, Shuang Ho Hospital, New Taipei City, Taiwan 6Department of Radiation Oncology, Taipei Medical University Hospital, Taipei, Taiwan 7Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan 8Cancer Center, Taipei Medical University Hospital, Taipei, Taiwan 9Department of Otolaryngology, Head and Neck Surgery, Wan-Fang Hospital, Taipei, Taiwan 10Graduate Institute of Biomedical Materials and Engineering, College of Oral Medicine, Taipei Medical University, Taipei, Taiwan *These authors have contributed equally to this work Correspondence to: Chien-Ho Chen, e-mail: chenchho@tmu.edu.tw Yin-Ju Chen, e-mail: yjchen1113@gmail.com Keywords: nasopharyngeal carcinoma (NPC), annexin A2 (ANXA2), chemotherapy, radiotherapy, epithelial-mesenchymal transition (EMT) Received: January 29, 2015 Accepted: June 26, 2015 Published: July 09, 2015

29 January 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
CCChang-Yu Chen
Chang-Yu Chen
SUSatoshi Ueha
Satoshi Ueha
YIYoshiro Ishiwata
Yoshiro Ishiwata
SYShoji Yokochi
Shoji Yokochi
DYDe Yang
De Yang
KMKouji Matsushima
Kouji Matsushima
Background Transient depletion of CD4+ T cells results in tumor suppression and survival benefit in murine models; however, the tumor progression and recurrence still occur over more long-term monitoring of mice. Thus, we explored an additional strategy to enhance endogenous immune responses by an alarmin, high mobility group nucleosome binding protein 1 (HMGN1). Methods The anti-tumor effects of HMGN1, anti-CD4 depleting antibody, and their combined treatment were monitored in the Colon26 or the B16F10 subcutaneous murine models. The tumor-infiltrating CD8+ T cell proliferation, differentiation, exhaustion, and its gene expression were determined by flow cytometry, transcriptome analysis, and quantitative real-time PCR. Results Our results show that a systemic administration of low doses of HMGN1 with an anti-CD4 depleting antibody (HMGN1/αCD4) promoted expansion of CD8+ T cell populations (e.g. CD137+ PD-1+ and CD44hi PD-1+), recruited CCR7+ migratory dendritic cells to the tumor, and reduced co-inhibitory molecules (e.g. PD-1, LAG-3, and TIM-3) to counteract CD8+ T cell exhaustion. Conclusion The HMGN1/αCD4 treatment expanded effector CD8+ T cells and prolonged their anti-tumor activities by rescuing them from exhaustion, thus resulting in tumor regression and even rejection in long-term monitored mice.